05.04.2013 - Austrian and German researchers have presented a blood test to track prostate cancer development.
The new method offers huge benefits to patients who have to be monitored for prostate cancer recurrence by providing a less invasive approach than the currently used biopsies. Instead, study chiefs Jochen Geigl and Michael Speicher from Medical University of Graz and the University Medical Center Hamburg Eppendorf, took blood samples, isolated the patient’s DNA and analysed it using an Illumina benchtop sequencer.
Genomic signatures displayed abnormal copy numbers of specific genetic markers, which indicated resistance against hormone deprivation therapy, the most common form of treatment in men with metastatic prostate cancer. Although being a small scale study including only 25 patients the presence of prostate cancer was flagged by copy number mistakes in sequences such as NCOA2, PHLPP1 and TMPRSS2-ERG. As expected each person's cancer signature was slightly different, however patients whose cancer did not respond to castration all had increased copy numbers of genes for the androgen receptor (AR).
According to the researchers, "the simplicity and low cost of such liquid biopsies make these genetic tests an attractive alternative to traditional biopsies. Better genetic information resulting from these tests may also help target treatment, especially of castration-resistant prostate cancer and aid personalised therapy in the clinic." Two years ago, Swiss researchers had presented a blood test detecting protein biomarkers to track prostate cancer. However, Next-Generation Sequencing is much faster and cheaper.
29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.
24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.
23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.
16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.
15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.
10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more